FDA — authorised 2 March 2020
- Marketing authorisation holder: SANOFI AVENTIS US
- Status: approved
🇺🇸 Hu38Sb19 in United States
FDA authorised Hu38Sb19 on 2 March 2020
Marketing authorisation
Hu38Sb19 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Hu38Sb19 approved in United States?
Yes. FDA authorised it on 2 March 2020.
Who is the marketing authorisation holder for Hu38Sb19 in United States?
SANOFI AVENTIS US holds the US marketing authorisation.